Management Team and Board of Directors

George Skouteris, MD, D.Phil., FRCPath., Chief Executive Officer and member of the Board

Qualified in Medicine, in GMC’s (UK) specialist’s register. Doctor of Philosophy in Biochemistry & Molecular Biology (D.Phil., University of Oxford, 1988). He has served in various positions within the Academia such as Group Leader at the Department of Pathology, Duke University Medical Center, NC, US as senior Investigator at the German Cancer Research Centre (DKFZ, Heidelberg) & senior Lecturer, University College London, UK) for a total of 23 years.
Since 2002 he has continued in various R&D and medical director positions in Pharmaceutical companies to include Eli Lilly (Oncology), Roche Products Ltd. (Oncology & Hepatitis), Daiichi Sankyo Inc. (Neuropathic Pain) and GSK (Immunology & Oncology). He has co-authored about 40 peer-reviewed publications and edited 3 books, mostly in the signal transduction and receptor-ligand interactions arena.

Daniel Abrams, Chief Financial Officer and member of the Board

An experienced main board plc CFO and non-executive director in international companies across different sectors including FMCG (drinks industry), technology (biotech and electronic displays) and manufacturing (non-woven textiles and power and data cables). More than 30 years public company experience at listed plc and Nasdaq companies including 20 years as an executive main board director CFO, and also experienced  as a non-executive director and audit committee chair.
Extensive knowledge and long track record of success in strategy, audit, compliance and capital markets, leading many acquisitions and disposals and fund raisings in the UK and US. Experienced in change management and turnaround and restructuring and working capital cash management. Executive career in a variety of international large, small and midcap companies. Detailed experience of operating in developing markets including Asia, South America and Africa and Middle East as well as major developed markets.
Executive CFO and main board director at Volex plc, Fiberweb plc CDT Inc  and Xenova Group plc. Non-executive director and audit chair at BioCity Group and BIA. Senior finance roles include divisional CFO and VP Finance at PepsiCo and Head of Corporate Finance and Strategy at Diageo plc.
MA (Hons) Cambridge, barrister and member of Inner Temple, chartered accountant and FCA. Past panel member of the FRRP of the FRC and member of the IFT.

Domenico Merante MD, Chief Medical Officer

Result-driven and excellence-focused physician with 21 years international experience in the pharmaceutical industry in clinical development and medical affairs. Nico comes in the company with robust history in clinical research with focus on neuroscience, pain, mostly type 2 diabetes associated with obesity, diabetic complications, metabolism, hypertension, metabolic syndrome and endocrinology. He is in the specialist’s register of the General Medical Council (UK) for Endocrinology & Diabetes. Serving in European and US managerial positions in medical departments to include head of Clinical positioning with Novo Nordisk (1999-2000, UK) and he continued as Senior Clinical Research Physician with Elli Lilly with focus the launching of an insulin analogue (Humalog) and leading the development of ruboxistaurin mesylate (an oral molecule investigated for the treatment of diabetic maculopathy and neuropathy) (2000-2004). He continued his clinical development career with GSK for 2 years (2004-2006) as medical director in Diabetes, Metabolism and Cardiovascular before moving to Daiichi Sankyo (UK) as senior medical director leading the Frontier Opportunities and Pain Division of the company at global level. He was in charge of clinical development for Olmesartan (Hypertension) and later in charge for all the Pain programs of the company from late pre-clinical to Phase III, exploring voltage calcium gated channel ligands as well as Nav 1.7. sodium channel blocker (2006-2016). He has co-authored more than 70 peer-reviewed publications and delivered numerous invited talks to meetings and conferences in Endocrinology, Pain and metabolism-related topics.

Board of Directors

Patrick Aebischer MD,Ph.D. (Executive Advisor to the Board)

President of the Ecole Polytechnique Federale de Lausanne (EPFL) and Professor of Neurosciences at the EPFL. He is currently holding appointments as Vice Chairman of the Board of Directors of the Lonza Group Ltd, Basel (since April 2014), member of the Board of Directors of Nestlé (since 2015), Chairman of the Advisory Board of the Novartis Venture Fund (since 2014) and member of the Foundation Board of the Wyss Center for Bio and Neuro Engineering (since 2014).
Since 2013 he has been a member of the Foundation Board of the World Economic Forum, member of the Singapore Biomedical Sciences International Advisory Council (since 2013) and fellow of the American Institute for Medical and Biological Engineering and fellow of the Swiss Academy of Medical Sciences (since 1998). He has numerous scientific contributions in neurosciences and he has been a recipient of prestigious awards from Swiss and International public and non-governmental organizations.

John Robert Brown CBE FRSE, Independent Non-Executive Director

Dr. Brown was elected a Fellow of the Royal Society of Edinburgh in 2007, is an Honorary Professor and Dr Honoris Causa at the University of Edinburgh and was created CBE in 2011. His current non-executive Chairman assignments in Synpromics Ltd, Kyowa Kirin International
plc, Cell Therapy Catapult and the Roslin Foundation. Since leaving Acambis plc he has  developed a portfolio of interests in the private and public sectors. Dr. Brown was Chairman of CXR Biosciences Ltd and Mode Diagnostics Ltd, and Senior Non-
Executive Director of Vectura Group plc and Electrical Geodesics Inc. He was also Chairman of BTG plc, and Axis-Shield plc until 2012 and was a Director of Cambridge Antibody Technology plc until its acquisition by AstraZeneca.
In the public sector Dr. Brown is Chairman of the Cell Therapy Catapult and the BioMedical  Catalyst Major Awards Committee and a member of the Medical Research Council. He was Chairman of the Roslin Institute for nine years.
In Scotland Dr Brown is Co-Chair, with the Cabinet Secretary for Health, of the Life Sciences Industry Advisory Board (LISAB). He was appointed a Board member of the UK Technology Strategy Board at its inception in 2004 and became a Non-Executive Director on its conversion to NDPB status in 2007.

Nick Rodgers BA FCA MSI, Independent Non-Executive Director

Nick is an experienced chairman and non-executive director with a background as a successful corporate financier.
Significant exposure to companies in the healthcare, medical, biotechnology, environmental and technology sectors. Nick has advised on or been involved with over 100 acquisitions or disposals, some 40 flotations and in excess of 20 takeovers. Nick started his strategic finance career with Ernst & Young (1981-1989), responsible for the vetting of proposed transactions by public companies. Then he moved to Evolution Securities (1989-2003) as head of Life sciences and progressing as a joint head of Corporate Finance.
He has served a number of companies as non-executive director or as director and among them as Chairman of Oxford Biomedica plc (2004-2016), Ipso Ventures plc (2005-2013), Morvus technology  Ltd (2004-2012) and Spice Holdings plc (2004-2006).